Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin - PubMed (original) (raw)
Multicenter Study
. 2010 Jan 7;29(1):26-33.
doi: 10.1038/onc.2009.301. Epub 2009 Oct 5.
Y Laitman, T Rubinek, L Abramovitz, I Novikov, R Beeri, M Kuro-O, H P Koeffler, R Catane, L S Freedman, E Levy-Lahad, B Y Karlan, E Friedman, B Kaufman
Affiliations
- PMID: 19802015
- DOI: 10.1038/onc.2009.301
Multicenter Study
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin
I Wolf et al. Oncogene. 2010.
Abstract
Klotho is a transmembrane protein that can be shed and act as a circulating hormone and is a putative tumor suppressor in breast cancer. A functional variant of KLOTHO (KL-VS) contains two amino acid substitutions F352V and C370S and shows reduced activity. Germ-line mutations in BRCA1 and BRCA2 substantially increase lifetime risk of breast and ovarian cancers. Yet, penetrance of deleterious BRCA1 and BRCA2 mutations is incomplete even among carriers of identical mutations. We examined the association between KL-VS and cancer risk among 1115 Ashkenazi Jewish women: 236 non-carriers, 631 BRCA1 (185delAG, 5382insC) carriers and 248 BRCA2 (6174delT) carriers. Among BRCA1 carriers, heterozygosity for the KL-VS allele was associated with increased breast and ovarian cancer risk (hazard ratio 1.40, 95% confidence intervals 1.08-1.83, P=0.01) and younger age at breast cancer diagnosis (median age 48 vs 43 P=0.04). KLOTHO and BRCA2 are located on 13q12, and we identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation. Studies in breast cancer cells showed reduced growth inhibitory activity and reduced secretion of klotho F352V compared with wild-type klotho. These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers.
Similar articles
- Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Satagopan JM, et al. Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589 - The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. Satagopan JM, et al. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11352856 - Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB, Boyd AA, Volcik K, Richards CS. Roa BB, et al. Nat Genet. 1996 Oct;14(2):185-7. doi: 10.1038/ng1096-185. Nat Genet. 1996. PMID: 8841191 - BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.
Linger RJ, Kruk PA. Linger RJ, et al. FEBS J. 2010 Aug;277(15):3086-96. doi: 10.1111/j.1742-4658.2010.07735.x. Epub 2010 Jul 1. FEBS J. 2010. PMID: 20608970 Review.
Cited by
- Changes in expression of klotho affect physiological processes, diseases, and cancer.
Xuan NT, Hai NV. Xuan NT, et al. Iran J Basic Med Sci. 2018 Jan;21(1):3-8. Iran J Basic Med Sci. 2018. PMID: 29372030 Free PMC article. Review. - Klotho: a novel biomarker for cancer.
Zhou X, Wang X. Zhou X, et al. J Cancer Res Clin Oncol. 2015 Jun;141(6):961-9. doi: 10.1007/s00432-014-1788-y. Epub 2014 Aug 3. J Cancer Res Clin Oncol. 2015. PMID: 25086986 Review. - The potential roles of exosomes in pancreatic cancer initiation and metastasis.
Sun W, Ren Y, Lu Z, Zhao X. Sun W, et al. Mol Cancer. 2020 Sep 2;19(1):135. doi: 10.1186/s12943-020-01255-w. Mol Cancer. 2020. PMID: 32878635 Free PMC article. Review. - Promoter methylation and age-related downregulation of Klotho in rhesus monkey.
King GD, Rosene DL, Abraham CR. King GD, et al. Age (Dordr). 2012 Dec;34(6):1405-19. doi: 10.1007/s11357-011-9315-4. Epub 2011 Sep 16. Age (Dordr). 2012. PMID: 21922250 Free PMC article. - The role of Klotho in energy metabolism.
Razzaque MS. Razzaque MS. Nat Rev Endocrinol. 2012 Oct;8(10):579-87. doi: 10.1038/nrendo.2012.75. Epub 2012 May 29. Nat Rev Endocrinol. 2012. PMID: 22641000 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous